• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.一种KRAS GTP酶K104Q突变体通过抵消调控缺陷来保留下游信号传导。
J Biol Chem. 2017 Mar 17;292(11):4446-4456. doi: 10.1074/jbc.M116.762435. Epub 2017 Jan 30.
2
Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity.变构调节开关 II 结构域控制 KRAS 致癌性。
Cancer Res. 2023 Oct 2;83(19):3176-3183. doi: 10.1158/0008-5472.CAN-22-3210.
3
The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.GTPase RAC2 的超活化 E62K 突变导致免疫失调的分子基础。
J Biol Chem. 2020 Aug 21;295(34):12130-12142. doi: 10.1074/jbc.RA120.012915. Epub 2020 Jul 7.
4
RAS ubiquitylation modulates effector interactions.RAS 泛素化调节效应器相互作用。
Small GTPases. 2020 May;11(3):180-185. doi: 10.1080/21541248.2017.1371267. Epub 2017 Nov 29.
5
Mechanistic aspects of signaling through Ras in NIH 3T3 cells.NIH 3T3细胞中通过Ras信号传导的机制方面。
Science. 1992 Jul 31;257(5070):671-4. doi: 10.1126/science.1496380.
6
Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase).短小芽孢杆菌核糖核酸酶(Binase)对致癌性KRAS的直接抑制作用。
Biochim Biophys Acta. 2016 Jul;1863(7 Pt A):1559-67. doi: 10.1016/j.bbamcr.2016.04.005. Epub 2016 Apr 8.
7
A dominant negative RAS-specific guanine nucleotide exchange factor reverses neoplastic phenotype in K-ras transformed mouse fibroblasts.一种显性负性RAS特异性鸟嘌呤核苷酸交换因子可逆转K-ras转化的小鼠成纤维细胞中的肿瘤表型。
Oncogene. 2000 Apr 20;19(17):2147-54. doi: 10.1038/sj.onc.1203539.
8
KRAS K104 modification affects the KRAS-GEF interaction and mediates cell growth and motility.KRAS K104 修饰影响 KRAS-GEF 相互作用,并介导细胞生长和迁移。
Sci Rep. 2020 Oct 15;10(1):17447. doi: 10.1038/s41598-020-74463-5.
9
Insights into K-Ras 4B regulation by post-translational lysine acetylation.翻译后赖氨酸乙酰化对K-Ras 4B调控的见解。
Biol Chem. 2016 Oct 1;397(10):1071-85. doi: 10.1515/hsz-2016-0118.
10
Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.致癌性 RAS 异构体显示出对鸟嘌呤核苷酸交换因子 SOS2 的分级需求,以介导细胞转化。
Sci Signal. 2018 Sep 4;11(546):eaar8371. doi: 10.1126/scisignal.aar8371.

引用本文的文献

1
The ubiquitin code of RAS proteins: Decoding its role in cancer progression.RAS蛋白的泛素密码:解读其在癌症进展中的作用。
iScience. 2025 Jul 1;28(8):113029. doi: 10.1016/j.isci.2025.113029. eCollection 2025 Aug 15.
2
Elucidating Ras protein as a dual therapeutic target for inflammation and cancer: a review.阐明Ras蛋白作为炎症和癌症的双重治疗靶点:综述
Discov Oncol. 2025 Jun 7;16(1):1029. doi: 10.1007/s12672-025-02783-x.
3
Real time characterization of the MAPK pathway using native mass spectrometry.使用基质辅助激光解吸电离飞行时间质谱对丝裂原活化蛋白激酶(MAPK)信号通路进行实时表征。
Commun Biol. 2025 Apr 16;8(1):617. doi: 10.1038/s42003-025-08028-5.
4
Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer.研究胰腺癌潜在的分子机制、信号通路及新出现的治疗方法。
Front Oncol. 2024 Jul 17;14:1427802. doi: 10.3389/fonc.2024.1427802. eCollection 2024.
5
Intrinsically disordered proteins: Ensembles at the limits of Anfinsen's dogma.内在无序蛋白质:处于安芬森法则极限的集合体。
Biophys Rev (Melville). 2022 Mar 17;3(1):011306. doi: 10.1063/5.0080512. eCollection 2022 Mar.
6
Computational design and validation of effective siRNAs to silence oncogenic KRAS.用于沉默致癌性KRAS的有效小干扰RNA的计算设计与验证
3 Biotech. 2023 Nov;13(11):350. doi: 10.1007/s13205-023-03767-w. Epub 2023 Sep 29.
7
Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer.致癌性 KRAS 突变通过上调非小细胞肺癌中的 SIRT1 赋予化疗耐药性。
Exp Mol Med. 2023 Oct;55(10):2220-2237. doi: 10.1038/s12276-023-01091-0. Epub 2023 Oct 2.
8
Reverse vaccinology and immunoinformatics approaches to design multi-epitope based vaccine against oncogenic KRAS.基于反向疫苗学和免疫信息学方法设计针对致癌性 KRAS 的多表位疫苗
Med Oncol. 2023 Aug 29;40(10):283. doi: 10.1007/s12032-023-02160-0.
9
Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity.变构调节开关 II 结构域控制 KRAS 致癌性。
Cancer Res. 2023 Oct 2;83(19):3176-3183. doi: 10.1158/0008-5472.CAN-22-3210.
10
Potential biomarkers uncovered by bioinformatics analysis in sotorasib resistant-pancreatic ductal adenocarcinoma.通过生物信息学分析在索托拉西布耐药性胰腺导管腺癌中发现的潜在生物标志物。
Front Med (Lausanne). 2023 Jun 15;10:1107128. doi: 10.3389/fmed.2023.1107128. eCollection 2023.

本文引用的文献

1
Inhibition of RAS function through targeting an allosteric regulatory site.通过靶向变构调节位点抑制RAS功能。
Nat Chem Biol. 2017 Jan;13(1):62-68. doi: 10.1038/nchembio.2231. Epub 2016 Nov 7.
2
Insights into K-Ras 4B regulation by post-translational lysine acetylation.翻译后赖氨酸乙酰化对K-Ras 4B调控的见解。
Biol Chem. 2016 Oct 1;397(10):1071-85. doi: 10.1515/hsz-2016-0118.
3
Structures of Ras superfamily effector complexes: What have we learnt in two decades?Ras 超家族效应器复合物的结构:二十年来我们学到了什么?
Crit Rev Biochem Mol Biol. 2015 Mar-Apr;50(2):85-133. doi: 10.3109/10409238.2014.999191. Epub 2015 Apr 1.
4
Drugging the undruggable RAS: Mission possible?靶向不可成药的 RAS:可能完成的任务?
Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17.
5
Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.特定突变的RAS致癌性解释了黑色素瘤中NRAS密码子61的选择。
Cancer Discov. 2014 Dec;4(12):1418-29. doi: 10.1158/2159-8290.CD-14-0729. Epub 2014 Sep 24.
6
Dragging ras back in the ring.将 ras 拖回拳击场。
Cancer Cell. 2014 Mar 17;25(3):272-81. doi: 10.1016/j.ccr.2014.02.017.
7
Differences in the regulation of K-Ras and H-Ras isoforms by monoubiquitination.K-Ras 和 H-Ras 异构体的单泛素化调节的差异。
J Biol Chem. 2013 Dec 27;288(52):36856-62. doi: 10.1074/jbc.C113.525691. Epub 2013 Nov 18.
8
A comparative CEST NMR study of slow conformational dynamics of small GTPases complexed with GTP and GTP analogues.一项关于与GTP及GTP类似物复合的小GTP酶缓慢构象动力学的对比性化学交换饱和转移核磁共振研究。
Angew Chem Int Ed Engl. 2013 Oct 4;52(41):10771-4. doi: 10.1002/anie.201305434. Epub 2013 Aug 22.
9
Structural analysis of autoinhibition in the Ras-specific exchange factor RasGRP1.Ras特异性交换因子RasGRP1中自抑制的结构分析
Elife. 2013 Jul 30;2:e00813. doi: 10.7554/eLife.00813.
10
HDAC6 and SIRT2 regulate the acetylation state and oncogenic activity of mutant K-RAS.组蛋白去乙酰化酶 6 和 SIRT2 调节突变型 K-RAS 的乙酰化状态和致癌活性。
Mol Cancer Res. 2013 Sep;11(9):1072-7. doi: 10.1158/1541-7786.MCR-13-0040-T. Epub 2013 May 30.

一种KRAS GTP酶K104Q突变体通过抵消调控缺陷来保留下游信号传导。

A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation.

作者信息

Yin Guowei, Kistler Samantha, George Samuel D, Kuhlmann Nora, Garvey Leslie, Huynh Minh, Bagni Rachel K, Lammers Michael, Der Channing J, Campbell Sharon L

机构信息

From the Department of Biochemistry and Biophysics.

Department of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy.

出版信息

J Biol Chem. 2017 Mar 17;292(11):4446-4456. doi: 10.1074/jbc.M116.762435. Epub 2017 Jan 30.

DOI:10.1074/jbc.M116.762435
PMID:28154176
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5377764/
Abstract

The KRAS GTPase plays a critical role in the control of cellular growth. The activity of KRAS is regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins (GAPs), and also post-translational modification. Lysine 104 in KRAS can be modified by ubiquitylation and acetylation, but the role of this residue in intrinsic KRAS function has not been well characterized. We find that lysine 104 is important for GEF recognition, because mutations at this position impaired GEF-mediated nucleotide exchange. Because the KRAS K104Q mutant has recently been employed as an acetylation mimetic, we conducted a series of studies to evaluate its and cell-based properties. Herein, we found that KRAS K104Q exhibited defects in both GEF-mediated exchange and GAP-mediated GTP hydrolysis, consistent with NMR-detected structural perturbations in localized regions of KRAS important for recognition of these regulatory proteins. Despite the partial defect in both GEF and GAP regulation, KRAS K104Q did not alter steady-state GTP-bound levels or the ability of the oncogenic KRAS G12V mutant to cause morphologic transformation of NIH 3T3 mouse fibroblasts and of WT KRAS to rescue the growth defect of mouse embryonic fibroblasts deficient in all genes. We conclude that the KRAS K104Q mutant retains both WT and mutant KRAS function, probably due to offsetting defects in recognition of factors that up-regulate (GEF) and down-regulate (GAP) RAS activity.

摘要

KRAS GTP酶在细胞生长控制中起着关键作用。KRAS的活性受鸟嘌呤核苷酸交换因子(GEFs)、GTP酶激活蛋白(GAPs)以及翻译后修饰的调节。KRAS中的赖氨酸104可被泛素化和乙酰化修饰,但该残基在KRAS固有功能中的作用尚未得到充分表征。我们发现赖氨酸104对GEF识别很重要,因为该位置的突变会损害GEF介导的核苷酸交换。由于KRAS K104Q突变体最近被用作乙酰化模拟物,我们进行了一系列研究来评估其体外和基于细胞的特性。在此,我们发现KRAS K104Q在GEF介导的交换和GAP介导的GTP水解方面均表现出缺陷,这与核磁共振检测到的KRAS局部区域的结构扰动一致,这些区域对于识别这些调节蛋白很重要。尽管在GEF和GAP调节方面存在部分缺陷,但KRAS K104Q并未改变稳态GTP结合水平,也未改变致癌性KRAS G12V突变体导致NIH 3T3小鼠成纤维细胞形态转化以及野生型KRAS挽救所有基因缺陷的小鼠胚胎成纤维细胞生长缺陷的能力。我们得出结论,KRAS K104Q突变体保留了野生型和突变型KRAS的功能,这可能是由于上调(GEF)和下调(GAP)RAS活性的因子识别方面的抵消缺陷所致。